135 related articles for article (PubMed ID: 35474890)
1. A novel prognostic model for Japanese patients with newly diagnosed bone-metastatic hormone-naïve prostate cancer.
Miyoshi Y; Yasui M; Yoneyama S; Kawahara T; Nakagami Y; Ohno Y; Iizuka J; Tanabe K; Hashimoto Y; Tsumura H; Tabata KI; Iwamura M; Yano A; Kawakami S; Uemura H
BJUI Compass; 2021 Mar; 2(2):105-114. PubMed ID: 35474890
[TBL] [Abstract][Full Text] [Related]
2. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial.
Buelens S; Poelaert F; Dhondt B; Fonteyne V; De Visschere P; Ost P; Verbeke S; Villeirs G; De Man K; Rottey S; Decaestecker K; Lumen N
Urol Oncol; 2018 Apr; 36(4):158.e13-158.e20. PubMed ID: 29336978
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study.
Kawahara T; Yoneyama S; Ohno Y; Iizuka J; Hashimoto Y; Tsumura H; Tabata KI; Nakagami Y; Tanabe K; Iwamura M; Uemura H; Miyoshi Y
Biomed Res Int; 2020; 2020():7804932. PubMed ID: 32714984
[TBL] [Abstract][Full Text] [Related]
4. Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer.
Buelens S; De Bleser E; Dhondt B; Verla W; Decaestecker K; Ost P; Fonteyne V; De Man K; Standaert C; Rottey S; Lumen N
World J Urol; 2019 Dec; 37(12):2565-2571. PubMed ID: 30132067
[TBL] [Abstract][Full Text] [Related]
5. Impact of nutritional status on the prognosis of patients with metastatic hormone-naïve prostate cancer: a multicenter retrospective cohort study in Japan.
Okamoto T; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
World J Urol; 2019 Sep; 37(9):1827-1835. PubMed ID: 30511214
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer.
Sun J; Tian T; Wang N; Jing X; Qiu L; Cui H; Liu Z; Liu J; Yan L; Li D
Front Endocrinol (Lausanne); 2024; 15():1338420. PubMed ID: 38384968
[TBL] [Abstract][Full Text] [Related]
7. PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
Barbato F; Fendler WP; Rauscher I; Herrmann K; Wetter A; Ferdinandus J; Seifert R; Nader M; Rahbar K; Hadaschik B; Eiber M; Gafita A; Weber M
J Nucl Med; 2021 May; 62(12):1747-50. PubMed ID: 33990403
[TBL] [Abstract][Full Text] [Related]
8. Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men.
Nakagawa R; Iwamoto H; Makino T; Naito R; Kadomoto S; Akatani N; Yaegashi H; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Takamatsu A; Yoshida K; Mizokami A
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230745
[TBL] [Abstract][Full Text] [Related]
9. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
[TBL] [Abstract][Full Text] [Related]
10. Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy.
Narita S; Nomura K; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nagashima K; Habuchi T
Cancer Med; 2019 Nov; 8(15):6566-6577. PubMed ID: 31508900
[TBL] [Abstract][Full Text] [Related]
11. Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients.
Kanesaka M; Sakamoto S; Yamada Y; Rii J; Maimaiti M; Sazuka T; Imamura Y; Komiya A; Akakura K; Ikehara Y; Nakatsu H; Ichikawa T
Prostate Int; 2021 Dec; 9(4):208-214. PubMed ID: 35059359
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight protein tyrosine phosphatase expression as a prognostic factor for men with metastatic hormone-naïve prostate cancer.
Ohtaka M; Miyoshi Y; Kawahara T; Ohtake S; Yasui M; Uemura K; Yoneyama S; Hattori Y; Teranishi JI; Yokomizo Y; Uemura H; Miyamoto H; Yao M
Urol Oncol; 2017 Oct; 35(10):607.e9-607.e14. PubMed ID: 28641939
[TBL] [Abstract][Full Text] [Related]
13. Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients.
Xie GS; Li G; Li Y; Pu JX; Huang YH; Li JH; Yin HM
Chin Med J (Engl); 2019 Nov; 132(22):2684-2689. PubMed ID: 31725446
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment Lymphocyte to C-Reactive Protein Ratio: An Independent Predictor of Overall Survival in Metastatic Hormone-Naïve Prostate Cancer Patients.
Sasaki T; Takahashi T; Sekito S; Kanda H; Higashi S; Masui S; Kojima T; Matsuura H; Nishikawa K; Akamatsu S; Okugawa Y; Kobayashi T; Inoue T
Clin Genitourin Cancer; 2023 Dec; 21(6):e474-e484. PubMed ID: 37301664
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis.
Narita T; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Shimoda J; Kawaguchi T; Ishidoya S; Mitsuzuka K; Arai Y; Ito A; Tsuchiya N; Habuchi T; Ohyama C
Transl Androl Urol; 2021 Jan; 10(1):417-425. PubMed ID: 33532329
[TBL] [Abstract][Full Text] [Related]
16. Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score ≥8.
Morozumi K; Mitsuzuka K; Narita S; Takahashi M; Kawamura S; Tochigi T; Arai Y; Hoshi S; Shimoda J; Ishidoya S; Okamoto T; Hatakeyama S; Sakurai T; Tsuchiya N; Ohyama C; Habuchi T; Ito A
Int J Urol; 2022 Apr; 29(4):324-331. PubMed ID: 35042278
[TBL] [Abstract][Full Text] [Related]
17. Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer.
Iacovelli R; Ciccarese C; Mosillo C; Bimbatti D; Fantinel E; Stefani L; Simbolo M; Romano M; Mazzarotto R; Brunelli M; Bria E; Scarpa A; Lawlor RT; Artibani W; Tortora G
Target Oncol; 2018 Oct; 13(5):649-655. PubMed ID: 30167971
[TBL] [Abstract][Full Text] [Related]
18. Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer.
Ebbinge M; Berglund A; Varenhorst E; Hedlund PO; Sandblom G;
BJU Int; 2018 Oct; 122(4):583-591. PubMed ID: 29611275
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer.
Nishimoto M; Fujita K; Yamamoto Y; Hashimoto M; Adomi S; Banno E; Saito Y; Shimizu N; Mori Y; Minami T; Nozawa M; Nose K; Hirayama A; Yoshimura K; Uemura H
Transl Cancer Res; 2022 Aug; 11(8):2681-2687. PubMed ID: 36093511
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer.
Akamatsu S; Kubota M; Uozumi R; Narita S; Takahashi M; Mitsuzuka K; Hatakeyama S; Sakurai T; Kawamura S; Ishidoya S; Hoshi S; Ishida M; Mizuno K; Ogura K; Goto T; Terada N; Kobayashi T; Yamasaki T; Inoue T; Tsuchiya N; Ohyama C; Arai Y; Habuchi T; Morita S; Ogawa O
Eur Urol Oncol; 2019 May; 2(3):320-328. PubMed ID: 31200847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
